Disease-stabilizing treatment based on all-trans retinoic acid and valproic acid in acute myeloid leukemia – identification of responders by gene expression profiling of pretreatment leukemic cells

Table 3 An overview of individual genes that belong to the 5 the GO-terms Nucleic acid binding/transcription factor/hydrolases/enzyme modulation/receptors and their expression in primary human AML cells – effects of in vivo treatment with the triple combination on the gene expression profile

Comparison (Number of genes included in the comparison)	Nucleic acid binding transcription factor		Hydrolases		Enzyme Modulation		Receptors
Comparison (Number of genes included in the comparison)	Increased	Decreased	Increased	Decreased	Increased	Decreased	Increased	Decreased
Day 1 versus day 3^a	FOXB1 JRKL	SALL3	ETHE1			RBP1 KIAA244		GRM1 IGFALS PTCHD1
Day 3 versus day 8^b	RSPH9 SIRT6 ONECUT		SIRT6	KLK1	ITI4 ANGBL3	KLK1 GNG12	AVPR1B	HS.344170 KLK1 AVPR1B GALR2
Day 1 versus day 8^c	NR2F1 PRDM13	ZBTB7C			CCNE2	SIPA1L1 DYNLL2 ITIH3	MRGPRX4 HCRTR1 UNC5B GPR151	GRM1 AVPR1A LRRC55

These five terms included a major part of the genes that showed differential expression when comparing responders and non-responders. Only genes with known annotations were included in the Panther analysis (and thereby in this table) that forms the basis for the table. The table presents those genes belonging to these five terms altered during treatment. The terms Increased/decreased expression means that the indicated genes showed increased/decreased expression during the investigated therapeutic intervention, i.e. during ATRA treatment day 3, following addition of valproic acid plus theophyllamine day8 and following triple therapy day 8
^aIncreased or decreased on day 3 after ATRA therapy
^bIncreased or decreased on day 8 after addition of valproic acid plus theophyllamine
^cIncreased or decreased on day 8 after triple therapy

ISSN: 1471-2407